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ORAL CHRONIC GVHD IN CHILDREN—TREATMENT WITH TOPICAL
TACROLIMUS OINTMENT
Albert, M.H., Klein, B., Schuster, F., Binder, V., Nienhoff, C.,
Fu¨hrer, M., Borkhardt, A. Dr. von Haunersches Children’s Hospital,
Pediatric Hematology/Oncology, Munich, Germany.
Oral chronic graft versus host disease (GVHD) frequently pre-
sents as lichen-type changes, hyperkeratotic plaques, pseudomem-
branes, or decreased oral range of motion in patients with sclerotic
features of skin GVHD and is often associated with signiﬁcant
limitations of oral food intake and a generally decreased quality of
life. Decreased oral intake is especially problematic in children
with already reduced caloric uptake due to chronic gastrointestinal
GVHD. Systemic tacrolimus is well established and efﬁcacious for
prophylaxis and treatment of acute and chronic GVHD and topical
tacrolimus has shown activity in chronic GVHD skin lesions. We
therefore initiated a pilot study to investigate the safety and efﬁcacy
of topical tacrolimus ointment in pediatric stem cell transplant
recipients with debilitating oral chronic GVHD. Two patients (6
and 13 years) with -thalassemia were included in the study at 179
and 382 days post transplant respectively. Both suffered from
progressive onset, moderate to severe chronic GVHD with in-
volvement of the oral mucosa exhibiting lichen-type changes
alongside pain, erythema and small ulcerations of the oral mucosa.
One patient additionally presented with progressive sclerosis of the
lips limiting opening of the oral cavity. In both patients oral lesions
had been refractory to systemic GVHD treatment (cyclosporine 3
and 2 mg/kg respectively). After exclusion of infectious causes for
oral lesions, tacrolimus ointment 0.1% (Protopic, Fujisawa
Healthcare) was applied twice daily using a sterile gauze that was
inserted into both buccal pouches and left in place for 20 minutes
without rinsing the mouth afterwards. At a follow up of 24 and 14
weeks respectively, the only side effect observed was a slight burn-
ing discomfort after the ﬁrst application in one patient. Tacrolimus
was absorbed in both patients as exhibited by tacrolimus plasma
levels up to 4.2 and 5.6 ng/ml respectively. Pain, erythematous
lesions and ulcerations disappeared within 4 weeks of treatment in
both. Lichenoid changes markedly improved in both and range of
oral opening normalized in the patient affected. Systemic immu-
nosuppression was tapered during treatment with topical tacroli-
mus in both patients. We conclude that topical application of
tacrolimus ointment holds promise as a safe and efﬁcacious treat-
ment for oral chronic GVHD in children. These ﬁndings deserve
to be afﬁrmed in a larger prospective evaluation.
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TREATING DONOR MICE WITH PALIFERMIN PROTECTS AGAINST THE
DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE IN A PAREN-
TAL STRAIN3F1-HYBRID MODEL
Ellison, C.A.1,2, Fischer, J.M.M.1, Madkar, B.3, Gartner, J.G.1,4 1.
Department of Pathology, University of Manitoba, Winnipeg, MB,
Canada; 2. Manitoba Blood and Marrow Transplant Program, Cancer-
Care Manitoba, Winnipeg, MB, Canada; 3. BSc. (Medicine) Program,
University of Manitoba, Winnipeg, MB, Canada; 4. Department of
Immunology, University of Manitoba, Winnipeg, MB, Canada.
Treating recipient mice with palifermin protects against the
development of acute, lethal GVHD in murine models induced
without a conditioning regimen. This is associated not only with a
cytoprotective effect in the recipient mice, but also with a change
in the cytokine proﬁle. Whereas untreated recipients develop a
strong Th1-mediated immune response, our previous work using
the C57BL/63(C57BL/6  DBA/2)F1-hybrid model of acute
GVHD showed that palifermin-treated recipients develop a mixed
Th1/Th2 cytokine proﬁle, with a preponderance of Th2 cytokines.
Others have made similar observations. This ﬁnding suggested that
palifermin might also have potent immunoregulatory effects that
mitigate the development of acute GVHD. To study the immu-
noregulatory effects of palifermin in GVH mice independently of
cytoprotective effects that result from treating the recipients with
palifermin, we induced GVHD in (C57BL/6  DBA/2)F1 mice
using grafts from palifermin-treated, C57BL/6 donors. More than
80% of these recipients survived until at least day 150. When we
compared the percentages of total, non-adherent donor spleen
cells, as well as percentages of donor CD4 and donor CD8 on
days 4, 8 and 15 in recipients of grafts from palifermin-treated
donors and recipients of grafts from untreated donors, the per-
centages were lower in the former group at some of these early
time-points. By day 148, the percentages of total non-adherent
donor cells, donor CD4 and donor CD8 cells reached 39%,
21% and 14%, respectively, indicating that the graft had not been
aborted. The percentages of CD4 and CD8 cells were very
similar in grafts of pooled spleen and lymph node cells harvested
from palifermin-treated donors and from untreated donors. Inter-
estingly, the levels of cytotoxic activity directed against YAC-1 and
BW1100 target cells by splenic effector cells from palifermin-
treated donor mice were 2-fold and 5-fold higher, respectively,
when compared to those seen when splenocytes from untreated
donors were used. These ﬁndings show that the ability of palifer-
min to protect against the development of acute GVHD in this
model may be due, at least in part, to its immunoregulatory effects.
They further suggest that palifermin may exert these effects
through a mechanism that involves the activation of donor NK
and/or NKT cells. Supported by a CIHR Operating Grant to JGG
and CAE. Palifermin was kindly provided by Amgen, Inc.
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ALLOANTIGEN AFFINITY AND CD4 HELP DETERMINE SEVERITY OF
GRAFT-VERSUS-HOST DISEASE MEDIATED BY CD8 DONOR T CELLS
Yu, X.-Z.1, Albert, M.H.2, Anasetti, C.1 1. H. Lee Mofﬁtt Cancer
Center, Tampa, FL; 2. Dr. von Haunersches Children’s Hospital, Mu-
nich, Germany.
TCR afﬁnity dictates T cell selection in the thymus and also has a
high impact on the fate of peripheral T cells. Graft-versus-host disease
(GVHD) is a pathological process initiated by activation of donor T
cells after adoptive transfer into an allogeneic recipient. How TCR
afﬁnity affects the potential of alloreactive T cells to induce GVHD is
unclear. Using alloreactive CD4 and CD8 TCR transgenic (Tg)
T cells, GVHD models are presented that allow for the visualization
of how CD8 alloreactive T cells behave in response to alloantigens
with different TCR afﬁnity in the absence or presence of CD4 help.
In a non-myeloablative transplant model where GVHD lethality is
due to marrow aplasia, alloreactive CD8 TCR Tg T cells induced
signiﬁcantly more severe GVHD in the recipients that express an
intermediate afﬁnity alloantigen than in the recipients that express a
high afﬁnity alloantigen. In a myeloablative transplant model where
GVHD lethality is due to epithelium injury, CD8 TCR Tg cells
were also more pathogenic in the recipients with an intermediate
afﬁnity alloantigen than in those with a high afﬁnity alloantigen. The
presence of alloreactive CD4 TCR Tg cells enhanced the potential
of CD8 TCR Tg cells to cause GVHD in recipients with an
intermediate, but not with a high afﬁnity alloantigen. These ﬁndings
underscore that alloantigen afﬁnity and CD4 help control the fate and
pathogenicity of alloreactive CD8 T cells in vivo.
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GRAFT ENGINEERING USING EX VIVO METHODS TO LIMIT GvHD:
FLUDARABINE TREATMENT GENERATES SUPERIOR GvL EFFECTS IN
ALLOGENEIC BMT
Li, J.-M., Giver, C.R., Waller, E.K. Hematology/Oncology, Winship
Cancer Institute, Emory University, Atlanta, GA.
Background: The development of new strategies to inhibit graft
versus host disease ( GVHD) while preserving graft-versus-leukemia
(GvL) activity of donor lymphocytes remains an important challenge
in the ﬁeld of allogeneic bone marrow transplantation (BMT). Several
methods to treat donor lymphocytes ex vivo prior to infusion using
different immunosuppressive agents—ﬂudarabine, psoralen/UVA
(PUVA), or -irradiation—have been tested in allogeneic mouse
models of BMT. While each method has been shown to limit the
GvHD potential of donor cells, their safety, efﬁcacy and GvL activ-
ities have not been directly compared. Methods: Donor/recipient
pairs included MHC fully mismatched (H2b3H2k, H2k3H2b),
MHC haplo-mismatched (H2b3H2b/k, H2b3H2b/d), and MiHA
mismatched (H2k13H2k2) strain combinations. T-cell depleted BM
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